Triple Incretin Agonists in Diabetes Mellitus: Retatrutide Improves Lipid Profile and Decreases Blood Pressure

Abstract

This opinion article discusses the emerging potential of retatrutide, a triple incretin agonist, in managing lipid profiles and blood pressure in patients with diabetes mellitus. Retatrutide has shown promise in improving lipid parameters and lowering blood pressure in clinical trials, making it a valuable addition to the therapeutic arsenal for diabetes and its associated metabolic disorders. While its precise mechanisms remain to be fully elucidated, the observed benefits highlight its potential to challenge current paradigms in metabolic disease management. The evidence discussed herein, though compelling, requires further validation through larger and more diverse clinical studies.

Cite this article as: Hasbal NB, Bakır CN, Çopur S, Kanbay M. Triple incretin agonists in diabetes mellitus: retatrutide improves lipid profile and decreases blood pressure. Turk J Nephrol. 2025;34(1):65-69.